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Abstract
Although topical glucocorticoids (GCs) display potent anti-inflammatory activity in inflamed skin, 
they also can exert numerous harmful effects on epidermal structure and function. In contrast, 
topical applications of ligands of peroxisome proliferator-activated receptor-α (PPARα) not only 
reduce inflammation, and also improve cutaneous barrier homeostasis. Therefore, we examined 
whether sequential topical GCs followed by topical Wy14643 (a ligand of PPARα) might be more 
effective than either alone for atopic dermatitis (AD) in a hapten (oxazolone)-induced, murine 
model with multiple features of AD (Ox-AD). Despite expected anti-inflammatory benefits, 
topical GC alone induced: i) epidermal thinning; ii) reduced expression of involucrin, loricrin and 
filaggrin; and iii) allowed outside-to-inside penetration of an epicutaneous tracer. While Wy14643 
alone yielded significant therapeutic benefits in mice with mild or moderate Ox-AD, it was less 
effective in severe Ox-AD. Yet, topical applications of Wy14643 after GC was not only 
significantly effective comparable to GC alone, but it also prevented GC-induced structural and 
functional abnormalities in permeability barrier homeostasis. Moreover, rebound flares were 
largely absent after sequential treatment with GC and Wy14643. Together, these results show that 
GC and PPARα ligand therapy together is not only effective but also prevents development of 
GC-induced side effects, including rebound flares, in murine AD.
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INTRODUCTION
Two major pathological features of atopic dermatitis (AD) are cutaneous permeability 
dysfunction and allergic inflammation, which drive each other in a classic vicious cycle 
(Elias PM et al., 2008). Therefore, treatment of AD ideally should incorporate methods that 
address both of these disease components. Topical glucocorticoids (GCs) have potent anti-
inflammatory effects, and represent standard treatment for AD, particularly in severe cases. 
However, improvement of AD symptoms comes at a price. As inflammation recedes, 
numerous harmful effects on epidermal structure and function emerge, which, in turn, could 
account for the commonly-observed clinical phenomena of tachyphylaxis and rebound flare-
ups following cessation of GC therapy (Hiratsuka et al., 1996; Kawakami et al., 2001; 
Fukaya et al., 2000). Specifically, GCs abrogate cutaneous permeability barrier homeostasis 
(Kao et al., 2003); suppress expression of epidermal antimicrobial peptide (Aberg et al., 
2007); inhibit the expression of epidermal differentiation-linked structural proteins, such as 
involucrin, filaggrin and loricrin (Demerjian et al., 2009); and inhibit epidermal proliferation 
in normal skin. Skin atrophy (Schacke et al., 2002), therefore, results not only from loss of 
dermis, but also as a consequence of multiple, negative effects on epidermis.
Activators of peroxisome proliferator-activated receptors (PPARs) α, β/δ, and γ, and liver X 
receptors (LXRs) which belong to the superfamily of nuclear hormone receptors, display 
potent, but largely positive effects on epidermal structure and function in normal and 
diseased skin (rev. in Schmuth et al., 2008). Earlier studies have shown that PPAR and LXR 
activators display substantial anti-inflammatory activity in murine models of both irritant 
and acute allergic contact dermatitis (Sheu et al., 2002; Fowler et al., 2003), and reverse 
epidermal hyperplasia while normalizing epidermal differentiation in a hyperproliferative 
disease model in mice (Komuves et al., 2000). These earlier results suggest that PPAR and 
LXR activators could mitigate several features of inflammatory dermatoses; and conversely, 
that their activators could be useful for the treatment of such diseases, including AD. 
Expression of PPARα is reduced in atopic lesional skin, and topical treatment with a 
PPARα activator prevents emergence of murine AD (Staumont-Salle et al., 2008), 
suggesting that a reduction in PPARα signaling might contribute to the pathogenesis of AD. 
More recently, we showed that topical activators/ligands of PPARα display potent anti-
inflammatory benefits in another murine model of AD (Hatano et al., 2010).
Co-treatment with certain PPAR activators reverses a variety of adverse effects of the 
topical GC treatment on normal murine epidermis (Demerjian et al., 2009); namely, co-
applications of a PPARα ligand normalized the expression of differentiation-linked 
structural proteins (involucrin, filaggrin and loricrin); keratinocyte proliferation and 
epidermal thickness; and permeability barrier homeostasis. Therefore, we postulated that 
combination treatment of AD with both GC and a PPARα activator could be not only at 
least as effective as treatment with GC alone, but that it also could prevent emergence of 
GC-related, epidermal side effects. Thus, in the present study, we compared the efficacy of 
sequential combination therapy with a super-potent GC (clobetasol) plus a PPARα ligand, 
with the GC and PPARα ligand alone. We chose PPARα, rather than a PPARβ/δ or LXR 
ligand, as our therapeutic target, because first, more is known about its potential role in the 
pathogenesis of AD (Staumont-Salle et al., 2008), and because certain PPAR activators 
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improve inflammation and barrier function in our previously-established, hapten-induced 
murine model of AD (Man and Hatano et al., 2008). We report here that treatment with the 
activator of PPARα ligand, Wy14643, by itself, significantly improves mild-to-moderate 
disease but is less effective in more severe dermatitis. Second, we found that treatment with 
the super-potent GC, with Wy14643 not only was highly effective, even in severe 
dermatitis, but it also prevented the emergence of GC-induced, epidermal side-effects and 
rebound flares of dermatitis.
RESULTS
Efficacy of the PPARα activator, super-potent glucocorticoid and combination therapy
We first examined the efficacy of clobetasol propionate, a super-potent GC, and Wy14643 
in Ox-AD mice with features of AD of increasing severity, assessed as changes in clinical 
appearance, histological features, T cell infiltration, and basal TEWL. (Recent studies have 
demonstrated that TEWL correlates well with clinical [inflammatory] status in AD)
(Sugarman et al., 2003; Angelova-Fischer et al., 2005). Topical application of Wy14643 
alone for 4 days improved clinical appearance and reduced TEWL in Ox-AD mice with 
‘moderate’ dermatitis (initial TEWL values ≤ 25 g/m2/h), but exacted little effects in Ox-AD 
mice with initial TEWL values ≥25 g/m2/h (Fig. 1a). By contrast, topical application of 
clobetasol propionate alone for 4 days was uniformly effective, even in animals with severe 
dermatitis. While topical application of Wy14643 alone for 4 days was less effective than 
GC alone for severe Ox-AD, the sequential combination of GC plus Wy14643 (i.e., 
experimental day 1, GC alone; from day 2 to day 4, Wy14643 alone) reduced TEWL even 
when lesions were severe, and it did so to the same extent as GC alone. The sequential 
combination of GC plus vehicle was not effective for severe dermatitis (Fig. 1b). In parallel 
with alterations of TEWL, infiltration of CD3-positive cells also declined after treatment 
either with GC alone or with the sequential combination of GC and Wy14643. Infiltration of 
CD3-positive cells also declined after treatment with the combination of GC and vehicle 
(Fig. 1c), but to a lesser extent than either GC alone or the combination of GC and 
Wy14643.
The sequential combination of GC and the PPARα activator did not dysplay any 
emergence of GC-induced epidermal side effects
In parallel with the apparent therapeutic benefits described above, GC alone and the 
sequential combination of GC plus Wy14643 significantly normalized epidermal 
hyperplasia in Ox-AD mice, while, in contrast, thinning of the epidermis was readily 
apparent in Ox-AD mice that had been treated with GC alone (Fig. 2). In contrast, lesions 
treated with the sequential combination of GC and Wy14634 did not display epidermal 
thinning (Fig. 2). As reported previously (Man and Hatano et al., 2008), expression of three 
differentiation-linked structural proteins (involucrin, loricrin and filaggrin) was abnormal 
and/or reduced in the outer epidermis of Ox-AD mice, and GC alone further reduced 
expression of these proteins (Fig. 1S). Yet, expression of the differentiation-linked proteins 
normalized after sequential treatment with GC and Wy14643..
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The sequential combination of GC and the PPARα activator dysplayed superior 
permeability barrier homeostasis to GC alone
We used three different methods to assess changes in permeability barrier status in treated 
Ox-AD mice. A quantitative, dye-penetration assay revealed that ‘outside-to-inside’ 
permeability improved significantly in lesions that had been treated with the sequential 
combination of GC and Wy14643 but not in lesions that had been treated with GC alone 
(Fig. 3a). Results with the electron-dense tracer, lanthanum nitrate, for ‘inside-to-outside’ 
penetration assessment supported the dye penetration assay (Figs. 3b, 3c and 3d). Finally, 
we compared the kinetics of recovery of permeability barrier function (% change in TEWL 
over time) at the end of each type of treatment; i.e., on experimental day 5, 48 h after the last 
Ox challenge dose. As shown in Figure 1b, values of TEWL at the end of the treatment 
period were similar in Ox-AD mice that had been treated with the sequential combination of 
GC and Wy14643 vs. sites treated with GC alone (Fig. 4a). However, 24 h after further 
acute abrogation of the barrier by tape stripping, TEWL declined to normal levels in Ox-AD 
mice that had been treated with the combination of GC and the PPARα activator, while 
TEWL remained higher than normal 48 h after tape stripping in Ox-AD mice that had been 
treated with GC alone (Fig. 4a). Accordingly, barrier recovery was greater in Ox-AD mice 
that had been treated with the sequential combination of GC and PPARα activator than it 
was in Ox-AD mice that had been treated with GC alone, at each time point examined (Fig. 
4b).
The sequential combination of GC and the PPARα ligand prevents rebound flares of Ox-
AD
We examined whether sequential application of GC and Wy14643 protects Ox-AD mice 
against the development of rebound flares, which are observed after treatment with GC 
alone. Eczematous lesions reappeared in mice within 4 days after discontinuation of 
treatment with GC alone. In contrast, re-development of such lesions was significantly 
reduced in Ox-AD mice that had been treated sequentially with GC plus Wy14643 (Fig. 5a). 
In parallel with these clinical observations, we found that both basal TEWL levels and the 
infiltration of CD3-positive cells were higher in mice treated with GC alone than in mice 
that had been treated with the sequential combination of GC and Wy14643 (Figs. 5b and 
5c). These results show that application of the PPARα activator after application of GC 
inhibits the re-emergence (= rebound flares) that occur after termination of treatment of Ox-
AD with GC alone.
DISCUSSION
Immunologic abnormalities and skin barrier dysfunction both contribute to the pathogenesis 
of AD (Elias et al., 2008), and effective therapy should address both issues. Treatment with 
PPARs and LXRs ligands appears promising because these agents not only have anti-
inflammatory activity but they also display positive effects on cutaneous permeability-
barrier homeostasis (Schmuth et al., 2008; Sheu et al., 2002; Fowler et al., 2003; Fluhr et al., 
2009). Some ligands of PPARα, β/δ (but not γ) and LXR, including the PPARα ligand 
Wy14643, have been shown to be effective in the murine model of AD used in the present 
study (Hatano et al., 2010), and involvement of PPARα in the pathogenesis of AD has been 
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suggested from studies in another murine model of AD (Staumont-Salle et al., 2008). 
However, the PPARα ligand by itself displayed limited therapeutic efficacy in severe lesions 
in our AD model, presumably reflecting its lower anti-inflammatory potency in comparison 
to the ‘super-potent’ GC, clobetasol propionate. Yet, the potency of GC comes at a price, 
because important side effects appear as inflammation recedes.
Demerjian et al. demonstrated recently that PPARα ligands prevent the epidermal 
abnormalities that are induced by super-potent GC, such as epidermal thinning and aberrant 
permeability-barrier homeostasis (Demerjian et al., 2009). Therefore, we postulated that the 
combination of GC plus a PPARα ligand could prove both more effective and safer for the 
treatment of AD than treatment with either agent alone. While the sequential combination of 
GC and Wy14643 was as effective for severe dermatitis lesions as GC alone, epidermal 
thinning, which was prominent after treatment with GC alone, was not observed after co-
treatment of severe dermatitis with GC plus Wy14643. In addition, the reduction in 
expression of three differentiation-linked structural proteins, namely, involucrin, loricrin, 
and filaggrin, induced during GC therapy alone, was prevented by the sequential application 
of GC and Wy14643, echoing previous results in similarly co-treated normal mouse skin 
(Demerjian et al., 2009). Thus, it appears that sequential applications of GC and the PPARα 
ligand not only maintains therapeutically efficacy, but it also blunts the harmful effects of 
GC alone on epidermal structure and function.
Both the quantitative, dye penetration assay and ultrastructural observations of lanthanum 
permeation revealed that barrier function is restored by co-treatment with the combination of 
GC and Wy14643, but not by GC alone. The beneficial effects of the sequential combination 
treatment on barrier homeostasis were consistent with the observed normalization of the 
expression of epidermal differentiation-linked structural proteins. Consistent with the 
abundant evidence that activators of PPARα have positive effects on barrier homeostasis 
(Schmuth et al., 2008), barrier recovery was also enhanced by sequential application of GC 
and Wy14643. Together these observations on barrier homeostasis likely account for the 
demonstrated ability of the PPARα ligand to prevent exacerbation of AD symptoms after 
discontinuation of GC therapy.
Taken together, the results of the present study suggest that combined sequential treatment 
with GC and Wy14643 could provide greater therapeutic benefits than treatment of AD with 
GC alone. Prior efforts to reduce the adverse effects of topical GC on cutaneous structure 
and function have involved moisturizers (Cork et al., 2003; Chamlin et al., 2002; Wirén et 
al., 2009), topical calcineurin inhibitors (Meurer et al., 2002; Furue et al., 2004), and an oral 
antihistamine, olopatadine hydrochloride (Tamura et al., 2005), both in patients with AD 
and in murine AD models. However, PPARα ligands, such as Wy14643, could appear to 
provide a superior choice for the prevention of the adverse effects of topical GC, because 
PPARα ligands have both anti-inflammatory effects and potent positive effects on cutaneous 
barrier homeostasis (Sheu et al., 2002; Komuves et al., 2000; Fluhr et al., 2009). 
Moisturizers have less anti-inflammatory activity than PPARα activators, and while topical 
calcineurin inhibitors display significant anti-inflammatory effects, they compromise both 
epidermal permeability-barrier functions and antimicrobial barrier function in mice (Kim et 
al., 2009). The oral administration of olopatadine hydrochloride has a positive effect on 
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permeability barrier homeostasis and inflammation (Amano et al., 2007; Tamura et al., 
2008), an observation that is consistent with the known ability of antihistamines (H1 and H2 
blockers) to improve barrier function (Ashida et al., 2001). However, it remains to be 
determined whether topical administration of olopatadine hydrochloride would also be 
effective for the treatment of AD, and in addition, it is unclear whether they can prevent the 
emergence of GC-related side effects.
According to the ‘outside-inside’ view of AD pathogenesis (Elias et al., 2008), 
normalization of barrier function should reduce the two major drivers of inflammation in 
AD, namely, the generation of cytokines which originate from perturbed corneocytes, and 
the transepidermal penetration of pro-inflammatory xenobiotes, such as haptens and 
microbial pathogens. Indeed, rebound flare-up was prevented only in Ox-AD mice in which 
the permeability barrier had been restored by sequential treatment with GC and the PPARα 
ligand. Thus, agents that have positive effects on permeability homeostasis should help us to 
prevent the negative effects of topical GC, including rebound flare-up.
In conclusion, the present study suggests that the sequential combination of topical GC and a 
PPARα ligand, Wy14634, might be an effective strategy for the treatment of human AD. 
The activators of PPAR or LXR that are most suitable for application with GC remain to be 
identified before this therapeutic strategy can be tested in a clinical setting. Finally, our 
study suggests that the Ox-AD mouse model might be useful for assessment of mechanisms 
involved in rebound flare-ups.
MATERIALS AND METHODS
Animals and materials
Female hairless (Hr-/Kud) mice (KYUDO Co., Fukuoka, Japan) were used at 12 to 48 
weeks of age. All animals were housed under conventional conditions and had free access to 
a commercial diet and water. WY14643 (PPARα activator), clobetasol propionate, 
oxazolone, MCDB153, Evans blue, and lanthanum nitrate were purchased from Sigma 
Chemical Co. (St. Louis, MO, USA). Affinity-purified rabbit primary antibodies, specific, 
respectively, for mouse filaggrin, loricrin and involucrin, were purchased from BabCo 
(Richmond, CA, USA). Biotinylated second antibodies, raised in goat against rabbit IgG, 
and an ABC-peroxidase kit were purchased from Vector Laboratories (Burlingame, CA, 
USA). A rabbit anti-human antibody against CD3 was purchased from Dako (Glostrup, 
Denmark).
Development and treatment of hapten -induced dermatitis with features of atopic 
dermatitis in mice
All animal procedures were approved by the “Ethics of Animal Experimentation 
Committee” of Oita University. Development of a hapten (oxazolone)-induced, murine 
model with multiple features of AD (Ox-AD) was described in our previous studies (Hatano 
et al., 2010; Man and Hatano et al., 2008). Animals were sensitized by two consecutive days 
of topical treatment with 50 µl of 5% oxazolone in acetone. After one week, mice were 
treated topically on both flanks with 60 µl of 0.5% oxazolone in ethanol once every other 
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day for an additional 4 weeks (total of 12 challenges). To achieve more severe lesions, the 
concentration of oxazolone used for elicitation of AD was higher than that (i.e., 0.1%) used 
in our previous studies (Hatano et al., 2010; Man and Hatano et al., 2008). After the tenth 
challenge, when the phenotype of AD-like, chronic allergic dermatitis had been established, 
the therapeutic effects of a topical super-potent, class 1 glucococorticoid (GC), namely, 
clobetasol propionate, and of a synthetic PPARα ligand, namely, Wy14643, were assessed 
by the method described in our previous report (Hatano et al., 2010) and as described in the 
legend to Table 1. One hour after the eleventh challenge, twice-daily applications of 60 µl of 
10 mM WY14643 in the vehicle, of 0.05% clobetasol propionate in the vehicle or of vehicle 
alone (a mixture of propylene glycol and ethanol, 7:3, v/v) were given for 4 days until 
experimental day 4. The twelfth challenge with oxazolone was administered one hour before 
the first application of GC, Wy14643 or vehicle on that day. As shown in Table 1, in some 
experimental groups, GC, Wy14643, or vehicle was applied for 4 consecutive days and in 
other groups, GC was applied only on the first day of the experiment, with 3 subsequent 
consecutive days of treatment with Wy14643 or vehicle. In some experiments, applications 
of oxazolone alone (i.e., without GC, Wy14643 or vehicle) was continued on the same areas 
on experimental day 5 and day 7 after therapeutic procedures had been discontinued.
Measurement of permeability barrier function
Basal transepidermal water loss (TEWL) was measured on individual flanks with a skin 
evaporative water recorder (Tewameter® TM210; Courage & Khazawa, Koln, Germany) 
immediately before each application of oxazolone and 48 h after the final application of 
oxazolone. The kinetics of permeability barrier recovery were examined as described 
previously (Kurahashi et al., 2008). Barrier disruption was achieved by sequential 
applications of cellophane tape (Nichiban, Tokyo, Japan). The procedure was stopped when 
TEWL reached 52 to 62 g/m2/h, as measured with the skin evaporative water recorder. 
Barrier recovery was monitored immediately after and 3, 6, 24, and 48 h after further 
disruption of sites of skin lesions. Recovery rates were calculated as described previously 
(Hou et al., 1991).
Immunohistochemistry
Full-thickness skin was harvested for immunohistochemical staining of filaggrin, loricrin, 
involucrin and for counting of CD3-positive T cells 48 h after the last application of 
oxazolone. Immunohistochemical staining was performed as described previously (Man and 
Hatano et al., 2008; Hatano et al., 2009). In brief, 5-µm paraffin-embedded sections were 
incubated with primary antibodies overnight at 4°C. After three washes, sections were 
incubated with second antibodies for 30 min. Staining was detected with the ABC-
peroxidase kit.
Quantitative morphology
The number of CD3-positive cells in a 250 µm × 250 µm area of dermis was determined in ≥ 
40 fields of dermis in each experimental group. The thickness of layers of epidermal 
nucleated cells, as observed in sections stained with hematoxylin and eosin, was measured at 
≥ 30 points, at intervals of 200 µm, in each experimental group. These quantitative 
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morphological examinations were performed under the condition in which an investigator 
could not find each sample belong to which experimental group.
Quantitative evaluation of outside-to-inside barrier function
Quantitative evaluation of outside-to-inside penetration of the skin was assessed with Evans 
blue dye. Skin samples, 16 mm in diameter, were collected from flanks 48 h after the last 
application of oxazolone and each sample was floated on MCDB 153 medium that contained 
1.8 mM CaCl2 with the outer epidermal surface of each sample exposed to the air. Then 100 
µl of 2% Evans blue in PBS were pipetted onto the outer epidermal surface of each skin 
explant. The dye was allowed to penetrate the skin for 4 h at room temperature, and then the 
surface of the skin was washed with PBS and gently wiped with a Kimwipe® (NIPPON 
PAPER CRECIA Co., Tokyo, Japan). After the washing procedures had been repeated three 
times, the center of each explant was biopsied with a 4-mm punch and each 4-mm disk was 
placed into 100 µl of 1 N KOH. After overnight incubation at 37°C, each sample was 
neutralized by the addition of 900 µl of a mixture of 0.6 N H3PO4 and acetone (5:13, v/v). 
After vigorous vortexing for a few seconds, the mixture was centrifuged at 3,000 rpm for 15 
min in KUBOTA RA-150AM (KUBOTA Co., Tokyo, Japan) and absorbance of 
supernatants was measured at 360 nm.
Electron microscopic observations of lanthanum nitrate penetration
The penetration of an electron-dense, water-soluble, low-molecular-weight tracer, 
lanthanum nitrate, from the outside toward the inside of the skin was assessed as described 
previously (Scharschmidt et al., 2009). In brief, skin samples, 16 mm in diameter, were 
collected from flanks 48 h after the last application of oxazolone and each sample was 
floated on MCDB 153 medium that contained 1.8 mM CaCl2, with the outward-facing, 
epidermal side of each sample exposed to air. Then 100 µl of 4% lanthanum nitrate in PBS 
were pipetted onto the outer epidermal surface of each explant. The dye was allowed to 
penetrate the skin for 3 h at room temperature. Then aldehyde-fixed biopsy specimens were 
fixed in either 0.25% ruthenium tetroxide or 1% aqueous osmium tetroxide that contained 
1.5% potassium ferrocyanide, as described previously (Hou et al., 1991). Ultrathin sections 
were examined with an electron microscope (Zeiss 10A; Carl Zeiss, Thornwood, NY) 
operated at 60 kV. Images were captured with Digital Micrograph 3.10.0 software (Gatan, 
Inc., Pleasanton, CA).
Statistical analysis
The statistical significance of differences was evaluated by Student’s t-test under normal 
distribution. A value of p<0.05 was considered statistically significant. Each result is given 
as a mean value ± SE, with the number of samples, n.
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Figure 1. Effects of treatment with a topical glucocorticoid (GC) and/or a PPARα activator on 
transepidermal water loss (TEWL) and the infiltration of CD3-positive cells
Transepidermal water loss [(a) and (b)] was measured as described in the text. In (b) and (c), 
Ox-AD mice in which TEWL was more than 25 g/m2/h on day 1 were used for the 
experiments. * p<0.05 vs. day 1. Numbers of CD3-positive cells on day 5 are shown in (c). n 
= 8 (four mice) in (a), n=6–10 (three to five mice) in (b) and n=40–80 (three to four mice) in 
(c). Abbreviation of label of each experimental group is according to the description in 
Table 1.
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Figure 2. Morphological changes in the epidermis
Skin samples were collected on experimental day 5 and were stained with hematoxylin and 
eosin as shown in (a). Bars =20 µm. Epidermal thickness was measured as described in the 
text and is shown in (b). n= 30–60 (three to four mice). Abbreviation of label of each 
experimental group is according to the description in Table 1.
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Figure 3. Assessment of outside-to-inside permeability-barrier function
The results of a quantitative penetration assay with Evans blue [(a); n=8 (four mice)] and 
electron micrographs [(b), (c) and (d)] are shown. See text for details. (b) Ox+veh, (c) Ox
+GC,GC and (d) Ox+GC,Wy. Block arrows indicate electron-dense material, namely, 
lanthanum nitrate, that has penetrated intercorneocyte spaces at the stratum corneum and 
stratum granulosum interface. Bars = 0.5 µm. Abbreviation of label for each experimental 
group is according to the description in Table 1.
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Figure 4. Recovery of permeability barrier function
On experimental day 5, the permeability barrier was disrupted by tape stripping as described 
in the text. Transepidermal water loss (TEWL) was examined before and after tape 
stripping, at each indicated time point, as described in the text. The horizontal dotted line 
indicates the mean values in normal control mice. The p-values in (a) refer to differences 
between Ox+GC,GC and Ox+GC,Wy. n = 10 (five mice). Abbreviation of label of each 
experimental group is according to the description in Table 1.
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Figure 5. Rebound of dermatitis after discontinuation of therapy
The every other day skin challenge with Ox alone was continued (day 5 and day 7) on the 
same area without GC nor Wy treatment. (a) Clinical appearance of mice on experimental 
day 9. (b) Alteration of transepidermal water loss (TEWL) (c) Density of CD3-positive cells 
in skin samples collected on day 9. The p-values refer to results from Ox+GC,GC and Ox
+GC,Wy. n = 12 (six mice) in (b), n = 24 (three mice) for GC, GC in (c) and n = 26 (three 
mice) for GC,Wy in (c). Abbreviation of label of each experimental group is according to 
the description in Table 1.
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Table 1
Treatment of hapten-induced atopic dermatitis in a murine model
Experimental groups Day1
(11th Ox1)
Day2 Day3
(12th Ox)
Day4
Ox+veh veh veh veh veh
Ox+Wy,Wy Wy Wy Wy Wy
Ox+GC,GC GC GC GC GC
Ox+GC,veh GC veh veh veh
Ox+GC,Wy GC Wy Wy Wy
1Ox, Oxazolone; veh, vehicle; Wy, Wy14643; and GC, glucocorticosteroid See text for details. This table indicates the experimental groups in the 
present study. The abbreviation of each group is provided in the text and the figure legends.
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